Speaker
Description
Since 2018, CYCLHAD has been engaged in treatments, research and development activities in proton therapy. Operating a single cancer treatment room using a Proteus®One commercial superconducting synchrocyclotron from IBA company, CYCLHAD is going to broaden its offer. A new milestone is currently underway to enable expanded heavy ions like carbon ion therapy capabilities by 2028, promising even more precise and effective cancer treatments. The unique set-up combining access to proton, helium and carbon ion, thanks to the C400 superconducting cyclotron from NHa, will bring for the first time in France cutting edge treatment for patients in partnership with a clinical institution and research laboratories. Moreover, the facility will make possible radio-biology and material sciences R&D as well as microelectronic hardness testing under irradiation.
This presentation is describing the whole CYCLHAD facility with its accelerators and irradiation rooms equipments feature.
